An Atypical Fibroxanthoma and Intradermal Nevus Collision Tumor-Potential for Misdiagnosis.

Atypical fibroxanthomas (AFX) are rare cutaneous tumors, which typically present as a solitary ulcerated papule or nodule on sun-damaged skin. Despite malignant-appearing features on histology, AFX typically pursue a benign clinical course. In rare instances, AFX can form collision tumors with other lesions. However, to the best of our knowledge, AFX in collision with a nevus has never been previously reported. In this study, we describe such a lesion for its novelty and challenge in diagnosis, as this case was originally considered to be melanoma arising in a nevus. On histologic examination, there were 2 distinct populations of cells; one composed of markedly atypical and pleomorphic epithelioid and oval to spindled cells, consistent with AFX, and the other, a bland-appearing intradermal nevus with congenital features. The AFX population stained positive with smooth muscle actin, CD10, and CD68 and was negative for S100, SOX10, Melan-A, desmin, pancytokeratin, CK5/6, and p63. Deep to this was a second population of small, bland-appearing melanocytes in a broad, band-like distribution. This unusual collision tumor between AFX and an intradermal nevus highlights the important role immunohistochemistry plays in avoiding the misdiagnosis and potential overtreatment of benign or low-grade lesions, and in identifying potential mimickers.

[1]  A. Galan,et al.  LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[2]  Megan Jones,et al.  Atypical Fibroxanthoma : A Case Report and Literature Review , 2017 .

[3]  B. Schilling,et al.  Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker , 2015, The American journal of surgical pathology.

[4]  A. Agaimy,et al.  Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy. , 2015, Anticancer research.

[5]  A. Lallas,et al.  Photoletter to the editor: Collision tumor of melanoma and atypical fibroxanthoma of the scalp. , 2014, Journal of dermatological case reports.

[6]  A. Hyatt,et al.  Collision of atypical fibroxanthoma and acantholytic squamous cell carcinoma in situ. , 2012, The American Journal of dermatopathology.

[7]  R. Scolyer,et al.  Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions , 2010 .

[8]  P. Heenan,et al.  Atypical Fibroxanthoma: A Histological and Immunohistochemical Review of 171 Cases , 2010, The American Journal of dermatopathology.

[9]  E. Calonje,et al.  Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review , 2010, Journal of cutaneous pathology.

[10]  T. McCalmont,et al.  Evaluation of CD10 and Procollagen 1 Expression in Atypical Fibroxanthoma and Dermatofibroma , 2008, The American journal of surgical pathology.

[11]  O. Ulusaraç,et al.  Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma. , 2008, Annals of clinical and laboratory science.

[12]  G. Scott,et al.  Metastasizing Atypical Fibroxanthoma (Cutaneous Malignant Histiocytoma) , 2005 .

[13]  S. Kossard,et al.  Procollagen 1 expression in atypical fibroxanthoma and other tumors , 2004, Journal of cutaneous pathology.

[14]  F. Angiero,et al.  Atypical fibroxanthoma and malignant fibrous histiocytoma of the skin. , 2003, Anticancer research.